Clinical Trial Update: The IRESSA Novel Head and Neck Chemotherapy Evaluation Study [Phase 2]

View source ↗

Summary

Phase 2 study evaluating IRESSA (gefitinib) in head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Squamous Cell Cancer, Cancer of Head and Neck | Phase 2 | Status: COMPLETED